Furthermore, Sharma et al. [50] further strengthened those findings by using multiple quantitative proteomic and immunoassay-based approaches for the serum proteomic analysis of different grades of meningiomas, which found that vimentin exhibited a very high level of differential expression in the meningioma patients as compared to the healthy subjects and that the increase of vimentin was associated to higher malignancy grades. This evidence concerns the gene VIM and meningioma.